Furthermore, the treatment regimens in this subgroup of patients also seemed to markedly reduce initial PIK3CA/AKT2/MTOR gene expression, a pathway frequently involved in maintaining stem cell and EMT character of tumour cells41 which might lead to a better outcome in this subgroup of non‐TNBC patients. This evidence concerns the gene AKT2 and neoplasm.